Diloxanide furoate

Paul G. Auwaerter, M.D., Kathryn Dzintars, Pharm.D., BCPS
Diloxanide furoate is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Drug not currently available for use in the U.S.
    • Also known in the literature as entamide furoate or entamide.
  • CDC conducted a study on the investigational use of the drug between 1977-1990.

NON-FDA APPROVED USES

  • Amebiasis, limited to the GI lumen, caused by Entamoeba histolytica.
  • As a combination therapy with other antiprotozoals, such as nitroimidazoles, for treating invasive or extraintestinal amebiasis. Diloxanide furoate is not a tissue amoebicide. Therefore, in extraintestinal infections of E. histolytica, another agent (specifically a "tissue amoebicide" like metronidazole) should be considered for use with diloxanide furoate.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Drug not currently available for use in the U.S.
    • Also known in the literature as entamide furoate or entamide.
  • CDC conducted a study on the investigational use of the drug between 1977-1990.

NON-FDA APPROVED USES

  • Amebiasis, limited to the GI lumen, caused by Entamoeba histolytica.
  • As a combination therapy with other antiprotozoals, such as nitroimidazoles, for treating invasive or extraintestinal amebiasis. Diloxanide furoate is not a tissue amoebicide. Therefore, in extraintestinal infections of E. histolytica, another agent (specifically a "tissue amoebicide" like metronidazole) should be considered for use with diloxanide furoate.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 18, 2022